相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis
Mehrdad Maz et al.
ARTHRITIS CARE & RESEARCH (2021)
Large-vessel involvement is predictive of multiple relapses in giant cell arteritis
Donatienne de Mornac et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)
Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis
Anael Dumont et al.
JOURNAL OF RHEUMATOLOGY (2020)
Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis
Sabine Mainbourg et al.
ARTHRITIS CARE & RESEARCH (2020)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Bernhard Hellmich et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis
Mattia Bellan et al.
CLINICAL RHEUMATOLOGY (2020)
Prognosis of large vessel involvement in large vessel vasculitis
Mathieu Vautier et al.
JOURNAL OF AUTOIMMUNITY (2020)
British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis
Sarah L. Mackie et al.
RHEUMATOLOGY (2020)
Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis
Jocelyn Ma et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)
Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study
Francesco Muratore et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
Wolfgang A. Schmidt et al.
RHEUMATOLOGY AND THERAPY (2020)
Risk profiling for a refractory course of giant cell arteritis: The importance of age and body weight
Eric Liozon et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse
Sara Monti et al.
FRONTIERS IN MEDICINE (2020)
Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions
Takahiko Sugihara et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Ischemic stroke in giant-cell arteritis: French retrospective study
Aaron Pariente et al.
JOURNAL OF AUTOIMMUNITY (2019)
Body mass index associates with disease relapse in patients with giant cell arteritis
Kotaro Matsumoto et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2019)
Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica
Yannick van Sleen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Pathologic Markers Determining Prognosis in Patients With Treated or Healing Giant Cell Arteritis
Harris Sultan et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis
Richard Conway et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Trial of Tocilizumab in Giant-Cell Arteritis
J. H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
Sergio Prieto-Gonzalez et al.
RMD OPEN (2017)
Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study
Cristian Labarca et al.
RHEUMATOLOGY (2016)
Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
Peter M. Villiger et al.
LANCET (2016)
Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study
Giovanna Restuccia et al.
MEDICINE (2016)
Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)
B. Bienvenu et al.
REVUE DE MEDECINE INTERNE (2016)
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
Raphaele Seror et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
Xiang Wan et al.
BMC MEDICAL RESEARCH METHODOLOGY (2014)
Relapses in Patients With Giant Cell Arteritis Prevalence, Characteristics, and Associated Clinical Findings in a Longitudinally Followed Cohort of 106 Patients
Marco A. Alba et al.
MEDICINE (2014)
Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis
Marco A. Alba et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis
Georgina Espigol-Frigole et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Giant cell arteritis: a multicenter observational study in Brazil
Alexandre Wagner Silva de Souza et al.
CLINICS (2013)
Statin Use in Giant Cell Arteritis: A Retrospective Study
Jean Schmidt et al.
JOURNAL OF RHEUMATOLOGY (2013)
Giant Cell Arteritis with or without Aortitis at Diagnosis. A Retrospective Study of 22 Patients with Longterm Followup
Olivier Espitia et al.
JOURNAL OF RHEUMATOLOGY (2012)
Relapses and Recurrences in Giant Cell Arteritis A Population-Based Study of Patients With Biopsy-Proven Disease From Northwestern Spain
Luciana Martinez-Lado et al.
MEDICINE (2011)
Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study
Sudha Visvanathan et al.
RHEUMATOLOGY (2011)
Clinical Relevance of Persistently Elevated Circulating Cytokines (Tumor Necrosis Factor α and Interleukin-6) in the Long-Term Followup of Patients With Giant Cell Arteritis
Ana Garcia-Martinez et al.
ARTHRITIS CARE & RESEARCH (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis:: A cross-sectional screening of fifty-four prospectively followed patients
Ana Garcia-Martinez et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
The epidemiology of glucocorticoid-associated adverse events
Allyson K. McDonough et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Clinical importance of the presence of giant cells in temporal arteritis
A. T. Armstrong et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Polymyalgia rheumatica and giant-cell arteritis
Carlo Salvarani et al.
LANCET (2008)
Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis - A randomized trial
Gary S. Hoffman et al.
ANNALS OF INTERNAL MEDICINE (2007)
The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
John P. A. Ioannidis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
Statin therapy does not seem to benefit giant cell arteritis
Javier Narvaez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2007)
Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis
M. C. Cid et al.
RHEUMATOLOGY (2006)
Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids - A double-blind, placebo-controlled, randomized prospective clinical trial
Mehrdad Mazlumzadeh et al.
ARTHRITIS AND RHEUMATISM (2006)
Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis:: A prospective study of 35 patients
D Blockmans et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2006)
Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis
J Hernández-Rodríguez et al.
RHEUMATOLOGY (2004)
Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis
A García-Martínez et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
A Proven et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis
GS Hoffman et al.
ARTHRITIS AND RHEUMATISM (2002)
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis
J Hernández-Rodríguez et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
Initial treatment of non-complicated giant-cell arteritis: 15 patients treated by pulse methylprednisolone 500 mg/d for three days followed by 20 mg/day oral prednisone.
L Sailler et al.
REVUE DE MEDECINE INTERNE (2001)
Combined treatment of giant-cell arteritis with methotrexate and prednisone -: A randomized, double-blind, placebo-controlled trial
JA Jover et al.
ANNALS OF INTERNAL MEDICINE (2001)
分享论文
